Year None202420232022202120202019201820172016 February 13, 2024 Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors Go to January 12, 2024 Medicenna Announces Appointment of New Auditor Go to January 9, 2024 Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab Go to Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4
February 13, 2024 Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors Go to
January 9, 2024 Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab Go to
